# Microglial reprogramming: a potential new frontier in enhancing immunotherapy for melanoma brain metastasis

## TL;DR

This paper explores how reprogramming brain microglia could improve immunotherapy for melanoma that spreads to the brain.

## Contribution

The study identifies NF-κB/RelA signaling as a key driver of microglial shift and proposes targeting it to enhance antitumor immunity.

## Key findings

- Microglia initially suppress tumors but later promote them in melanoma brain metastases.
- NF-κB/RelA signaling drives the shift in microglial function.
- Inhibiting this pathway reprograms microglia to support antitumor immunity.

## Abstract

The brain is a common site of metastatic dissemination in advanced melanoma. Due to limited access to samples from human brain metastases, our understanding of the tumor microenvironment in the brain lags behind that of other sites, and murine studies are therefore highly informative. Rodriguez‐Baena et al. conducted elegant studies of myeloid cells within melanoma brain metastases, demonstrating their plasticity and changes before and after colonization by melanoma cells. The immune‐inhibitory changes in microglial cells may be reversed or mitigated by inhibition of RelA/NF‐κB.

Microglia act as tumor suppressors during brain metastasis colonization but shift to a tumor‐promoting role after melanoma brain metastases form. NF‐κB/RelA signaling emerges as a key driver of this phenotypic shift. Targeting this pathway reprograms microglia into a pro‐inflammatory state, enhancing antitumor immunity and immune checkpoint inhibitor responses, offering a novel therapeutic avenue for melanoma brain metastasis.